Nuclidium - Crunchbase Company Profile & Funding

Q: Where is Nuclidium's headquarters?

Nuclidium is located in Basel, Basel-Stadt, Switzerland.

Q: Who invested in Nuclidium?

Nuclidium has 13 investors including Neva SGR And Kurma Partners.

Q: When was the last funding round for Nuclidium?

Nuclidium closed its last funding round on obfuscated from a Series B round.

Q: How much funding has Nuclidium raised to date?

Nuclidium has raised obfuscated.

Overview

Nuclidium

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Nuclidium

CB Rank

6923

Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.

Founded

obfuscation

Private

Series B

Basel, Basel-Stadt, Switzerland

11-50

www.swissnuclides.ch

Health Care

Health Diagnostics

Medical

Therapeutics

Funding Rounds

Series B

OBF

obfuscation

Series B

OBF

obfuscation

Grant

OBF

obfuscation

Key People

Leila Jaafar-Thiel: CEO and Founder
Claudia Halasz: CFO

Details

Legal Name

Swiss Nuclides AG

Also Known As

Swiss Nuclides

Operating Status

Active

Company Type

For Profit

Founders

Gustav Schulthess, Leila Jaafar-Thiel

About the Company

NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.

Phone Number

+41 78 326 6666

Contact Email

info@swissnuclides.ch

Predictions & Insights

Growth Insight

See this Growth Insight

Nuclidium is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

CuTrace™ platform

A platform that combines copper radiometals with cancer-targeting molecules to develop therapeutic and diagnostic programs.

NuriPro™

A 61Cu-based diagnostic and 67Cu-based therapeutic pair targeting PSMA for prostate cancer diagnosis and treatment.

Research & Development

Nuclidium is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B
obfuscated obfuscation	Series B - Nuclidium	9	obfuscated obfuscation	Angelini Ventures, EIB Global, Kurma Partners, Neva SGR, Wellington Partners	Series B

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Neva SGR	Yes	Series B - Nuclidium	Mario Costantini
Neva SGR	Yes	Series B - Nuclidium	Mario Costantini
Neva SGR	Yes	Series B - Nuclidium	Mario Costantini
Neva SGR	Yes	Series B - Nuclidium	Mario Costantini
Neva SGR	Yes	Series B - Nuclidium	Mario Costantini